menu
    • menu
    [{"orgOrder":0,"company":"Mabylon","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Financing","leadProduct":"MY006","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Mabylon","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Mabylon \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Mabylon \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Mabylon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MY006","moa":"Peanut allergen","graph1":"Immunology","graph2":"Phase I","graph3":"Mabylon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabylon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabylon \/ Undisclosed"},{"orgOrder":0,"company":"Mabylon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MY006","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Mabylon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabylon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabylon \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Mabylon

    Menu

    Mabylon

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mabylon

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Mabylon

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MY006

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and ...

                            Details : MY006 is a antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Peanut Hypersensitivity.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 16, 2025

                            Lead Product(s) : MY006

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mabylon

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Mabylon

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MY006

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mabylon AG Begins Phase I Trial of MY006 for Peanut Allergy.

                            Details : MY006, an unconjugated antibody targeting peanut allergen, shows promise in treating Peanut Allergy.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 11, 2025

                            Lead Product(s) : MY006

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mabylon

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Mabylon

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MY006

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $37.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006

                            Details : The funding will allow Mabylon to advance its lead program MY006, a tri-specific antibody for the prophylactic treatment of peanut allergy.

                            Product Name : MY006

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            August 12, 2025

                            Lead Product(s) : MY006

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $37.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.